A year of transformation, scale & international growth FY2026 FULL YEAR RESULTS ASX: BLS | August 2026 DISCLAIMER This presentation (Presentation) has been prepared by BLS Pharmaceuticals Limited ABN 97 084 464 193 (BLS or the Company).The information in this Presentation is of a...
BLS Investor Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
BLS Pharmaceuticals Limited on 6ix
In the deck
Earlier from BLS Pharmaceuticals
- BLS FY2026 Results Announcement
- Annual Report to shareholders
- BLS FY2026 Results Webinar 2 September 2026 8am AEST
- Application for quotation of securities - BLS
- BLS to Present at Coffee Microcaps 31/7/2026 at 11.30 am
Later from BLS Pharmaceuticals
- BLS FY2027 Guidance
- Appendix 4G Corporate Governance Statement
- S&P DJI Announces September 2026 Quarterly Rebalance
- Angus Walker Appointed Alternate Director to Edward Myer
- Initial Director's Interest Notice
Follow BLS Pharmaceuticals into a list and get an email when it puts out news.
Follow BLS Pharmaceuticals